Is Moderna Heading for a Critical Moment?
(NASDAQ: MRNA) has generated billions of dollars in sales and profit from its coronavirus vaccine. But the vaccine landscape is changing. As we move toward a post-pandemic world, demand is on the decline. And Moderna's vaccine isn't likely to bring in as much in revenue as it did in early pandemic days.
This doesn't mean the revenue opportunity is over, though. And the company could be heading for a big moment -- one that will give investors an idea of coronavirus vaccine revenue potential ahead. I'm talking about the fall vaccine season. Let's take a closer look at exactly how important this moment will be for Moderna.
First, a quick summary of Moderna's path so far: The biotech company burst onto the scene with not only a coronavirus vaccine, but one that used a new technology, called messenger RNA. These types of vaccines instruct the body to produce proteins to protect itself from a particular illness -- in this case, the coronavirus. Rival Pfizer also sells an mRNA vaccine. Together, both companies dominate the vaccine market.
Source Fool.com
Moderna Inc. Aktie
Klarer Community-Favorit: Moderna Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 120 €, festgelegt von der Community für Moderna Inc., zeigt ein Potenzial von 103.77%, was einer Verdopplung des aktuellen Kurses entspricht.
